Cinryze

Cinryze is a brand name for a medication containing human C1 inhibitor (human plasma-derived). It is a type of enzyme replacement therapy used for the long-term routine prevention of hereditary angioedema (HAE) attacks in adult and adolescent patients. HAE is a rare genetic disorder characterized by recurrent, unpredictable episodes of swelling in various parts of the body. Cinryze works by replacing the deficient or dysfunctional C1 inhibitor protein, which plays a crucial role in regulating inflammation and preventing swelling in HAE. The medication is administered intravenously. It is important to note that Cinryze is not intended for the acute treatment of HAE attacks or for other types of angioedema. The drug is manufactured by Takeda Pharmaceuticals. Its use is associated with potential side effects, and patients should consult with their healthcare provider for complete information regarding its administration, efficacy, and safety profile. The development and availability of Cinryze represent a significant advancement in the management of HAE, offering a prophylactic treatment option for individuals affected by this condition.